ArticleFrontiers in immunology2025
SLFN11 expression correlates with immune microenvironment and predicts prognosis in melanoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Schlafen family member 11 (SLFN11) has been implicated in cancer biology and immune modulation, but its expression patterns, prognostic value, and role in tumor immunity in melanoma remain incompletely defined. Methods: Through multi-omics analyses of public databases (The Human Protein Atlas, TIMER2, BEST) and functional validation, we characterized SLFN11 in melanoma. Functional assays were conducted in SLFN11-overexpressing melanoma cells to evaluate effects on M0 macrophage polarization, recruitment of macrophages and CD8⁺ T cells, and CD8⁺ T cell cytotoxic activity. Results: SLFN11 mRNA levels are reduced in skin cutaneous melanoma (SKCM) compared to normal skin, yet higher in metastatic lesions than in primary tumors. High SLFN11 expression correlates with favorable overall and progression-free survival across multiple independent melanoma cohorts, with consistent prognostic value across clinical subgroups (tumor stages, nodal/metastatic status). Multivariable Cox regression analysis, adjusting for factors like gender, age, and pathologic T/N/M stages, confirmed SLFN11 expression as an independent predictor of favorable overall survival. SLFN11 expression associates with enhanced infiltration of immune cells along with co-expression of immune checkpoint molecules. Furthermore, SLFN11 expression is associated with favorable prognosis in immunotherapy-treated patients. Functional assays show that SLFN11-overexpressing melanoma cells promote M0 macrophage polarization toward an M1 phenotype, enhance recruitment of macrophages and CD8⁺ T cells, and slightly increase CD8⁺ T cell cytotoxic activity. Conclusions: These findings provide evidence that SLFN11 is associated with immune microenvironment changes in melanoma, correlates with favorable prognosis, and may be linked to immunotherapy response, supporting its potential as a candidate biomarker and therapeutic target for further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.